Lupin Pharm, Cornerstone Enter Agreement for Suprax

Lupin, the Mumbai-based pharma major, has announced that its wholly owned subsidiary, Lupin Pharmaceuticals (LPI), has entered into an alliance with Cornerstone BioPharma as a promotion partner in the U.S. for its Suprax (cefixime) anti-infective. Suprax was approved in 2004 and has been promoted by LPI's pediatric focused sales force. This partnership represents a significant expansion in the scope of physician coverage for Suprax in the $1.2 billion U.S. oral suspension anti-infective market.

PharmaBiz (http://www.pharmabiz.com/article/detnews.asp?articleid=25886)